Piper Sandler Initiates Coverage on Beta Bionics (NASDAQ:BBNX)

Piper Sandler started coverage on shares of Beta Bionics (NASDAQ:BBNX) in a report released on Monday, Marketbeat Ratings reports. The firm set an “overweight” rating and a $26.00 price target on the stock. Piper Sandler’s target price points to a potential upside of 35.63% from the stock’s current price.

Several other brokerages also recently commented on BBNX. LADENBURG THALM/SH SH initiated coverage on Beta Bionics in a research note on Thursday, February 20th. They set a “neutral” rating and a $20.00 target price for the company. Leerink Partners started coverage on shares of Beta Bionics in a report on Monday. They set an “outperform” rating and a $28.00 price target on the stock. Baird R W raised shares of Beta Bionics to a “hold” rating in a research note on Thursday, February 20th. Finally, Robert W. Baird initiated coverage on shares of Beta Bionics in a report on Thursday, February 20th. They set a “neutral” rating and a $20.00 price target for the company. Three research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.83.

Beta Bionics Trading Down 6.9 %

Shares of BBNX opened at $19.17 on Monday. Beta Bionics has a 52-week low of $19.08 and a 52-week high of $24.50.

Insider Buying and Selling at Beta Bionics

In other Beta Bionics news, insider Mike Mensinger acquired 33,350 shares of Beta Bionics stock in a transaction that occurred on Friday, January 31st. The shares were bought at an average price of $17.00 per share, with a total value of $566,950.00. Following the completion of the purchase, the insider now directly owns 59,019 shares in the company, valued at $1,003,323. This trade represents a 129.92 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Hadley Harbor Aggre Wellington acquired 1,000,000 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The stock was bought at an average price of $17.00 per share, with a total value of $17,000,000.00. Following the completion of the acquisition, the insider now directly owns 3,901,599 shares of the company’s stock, valued at $66,327,183. This trade represents a 34.46 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Beta Bionics Company Profile

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.